Ovarian Cancer Articles | Page 2

Final Results Confirm OS Benefit Associated with Olaparib in Relapsed Platinum-Sensitive Serous Ovarian Cancer
Maintenance therapy with olaparib monotherapy provides clinically significant, long-term treatment benefits and is safe in patients with platinum-sensitive relapsed serous ovarian cancer.
Expert Discusses Rucaparib Maintenance in Ovarian Cancer
Jonathan Ledermann, MD, discussed these results, as well as the future of PARP inhibitors in the maintenance setting for patients with ovarian cancer.
Survey Shows Patients Consider Several Factors of Maintenance Therapy for Ovarian Cancer Treatment
Patients with ovarian cancer were unified in their responses regardless of age, disease stage, or whether they had primary or recurrent disease, and were more likely to opt to receive maintenance therapy if it could offer delay of disease progression and allow patients to maintain or improve their quality of life.
PALB2 Mutation Implicated in Higher Risk of Breast Cancer, Not Ovarian
Deleterious mutations in the PALB2 gene may account for the development of breast cancer in women with an elevated risk due to a family history of breast or ovarian cancer, but who test negative for the BRCA1 or BRCA2 genes.
Maintenance Rucaparib Extended PFS in Women with Platinum-Sensitive Recurrent Ovarian Cancer
Rucaparib delayed disease recurrence in the intent to treat population and across subgroups of women with ovarian cancer.
Secondary Cytoreductive Surgery Shows Promise in Ovarian Cancer
Jalid Sehouli, MD, PhD, discusses the significance of these findings in the treatment of patients with platinum-sensitive recurrent ovarian cancer.
No Overall Survival Advantage in Frontline Nintedanib With Chemotherapy in Advanced Ovarian Cancer
The final analysis of overall survival data from the phase III AGO-OVAR 12 trial of nintedanib plus carboplatin/paclitaxel versus carboplatin/paclitaxel alone in women with chemotherapy-naive advanced ovarian cancer did not demonstrate a survival advantage with the addition of nintedanib.
Salvage Surgery Improved PFS in Platinum-Sensitive Recurrent Ovarian Cancer
Patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score experienced prolonged progression-free survival after undergoing a second cytoreductive surgery followed by platinum-based chemotherapy.
Mixed Findings Show Dose-Dense Therapy Noninferior to IP Treatment in Ovarian Cancer
Paul Sabbatini, MD, discusses the recent data surrounding IP and dose-dense therapy and the next steps for both treatment approaches in ovarian cancer.
Robotic Laparoscopy Improves Outcomes for Patients With Ovarian Cancer, Reaffirms Role of Surgery
Mario M. Leitao, Jr, MD, FACOG, FACS, discusses how surgery retains its imperative role in ovarian cancer and sheds light on the challenges that still remain.
Publication Bottom Border
Border Publication